ArticleCanadian journal of veterinary research = Revue canadienne de recherche veterinaire2022
Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus.
Article in Canadian journal of veterinary research = Revue canadienne de recherche veterinaire, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats.Journal of feline medicine and surgery · 2025Guideline
- Post-marketing safety monitoring of sodium-glucose cotransporter 2 inhibitors for diabetes in cats: a pharmacovigilance study based on the FDA ADAE database.Journal of veterinary internal medicine · 2026Article
- Pharmacokinetics of Bexagliflozin After Intravenous and Oral Administration in Cats.Journal of veterinary pharmacology and therapeutics · 2026Article
- Effect of the sodium glucose transporter-2 inhibitor dapagliflozin on urine and blood biomarkers in dogs with heart disease.Journal of veterinary internal medicine · 2026Article
- Spectrum of veterinary care in feline diabetes mellitus.Journal of feline medicine and surgery · 2026Review
- Case Report: Bexagliflozin as an adjunct decongestive strategy in a cat with congestive heart failure and advanced chronic kidney disease.Frontiers in veterinary science · 2026Article
- Cushing's Syndrome associated with diabetes mellitus in a Persian cat: clinical features, diagnosis, and therapeutic management.Brazilian journal of veterinary medicine · 2026Article
- Glucose-Lowering Effects and Safety ofMicroorganisms · 2025Article
- Clinical therapeutics in feline medicine: updates for old and new drugs.Journal of feline medicine and surgery · 2025Review
- Efficacy and Safety of Non-Insulin Antidiabetic Drugs in Cats: A Systematic Review.Animals : an open access journal from MDPI · 2025Review
- Differential glycemic effects of DWP16001 in diabetic dogs according to baseline glycemic status: a multicenter randomized controlled trial.BMC veterinary research · 2025Article
- Faecal Microbiota Transplantation as an Adjuvant Treatment for Extraintestinal Disorders: Translating Insights from Human Medicine to Veterinary Practice.Veterinary sciences · 2025Review
- SGLT2 inhibitor use in the management of feline diabetes mellitus.Journal of veterinary pharmacology and therapeutics · 2025Review
- Sodium-glucose co-transporter 2 inhibitors: a pleiotropic drug in humans with promising results in cats.Frontiers in veterinary science · 2025Review
- Novel FDA-approved bexagliflozin drug for treating type 2 diabetes mellitus.Annals of medicine and surgery (2012) · 2024Article
- Signalment and laboratory findings in cats with diabetes mellitus in Germany: a retrospective review of laboratory submissions of 129,505 cats.Journal of feline medicine and surgery · 2024Article
- Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus.Journal of veterinary internal medicineArticle
- Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats.Journal of veterinary internal medicineArticle
- Feline acute patient physiologic and laboratory evaluation scores and other prognostic factors in cats with first-time diabetic ketoacidosis.Journal of veterinary internal medicineArticle
- Frequency, Risk Factors, and Mortality for Diabetes Mellitus in 1 225 130 Cats Under Primary Veterinary Care in the United Kingdom in 2019.Journal of veterinary internal medicineArticle
Corrections and comments
- Erratum issuedErratum.2023
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to investigate the effect of bexagliflozin on glycemic control in poorly regulated diabetic cats and to evaluate for adverse events associated with this medication. Sodium-glucose cotransporter 2 inhibitors are a newer class of drugs used in the management of humans with type 2 diabetes mellitus. The objective of this study was to evaluate the effect of the orally administered drug, bexagliflozin in a group of poorly regulated diabetic cats over a 4-week study period. Five client-owned cats with poorly controlled diabetes mellitus receiving insulin therapy were enrolled. Bexagliflozin was administered once daily. Serum fructosamine, serum biochemistry profile, and 10-hour blood glucose curves were assessed at baseline (Day 0), Day 14, and Day 28. All cats had a significant reduction in insulin dose requirement (
Indexed as
Identifiers
34975223PMC8697324W4206873351What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.